Suitability-for-Use Considerations for Prefilled Syringes - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Suitability-for-Use Considerations for Prefilled Syringes
The nature of their application and their mode of use mean that prefilled syringes meet the regulatory definitions of immediate packaging or container–closure systems.

Pharmaceutical Technology

Prefilled syringes have become important options in the packaging, distribution, and delivery of pharmaceutical solution products, particularly biopharmaceuticals. This container–closure system provides several practical advantages, including convenience in simplified drug administration; greater accuracy in filling (i.e., less likelihood of overfilling, which is common in other packaging–delivery options); and reduced instances of misidentification, improper dosing, and contamination (1). These advantages, along with a critical mass of commercially available syringe systems, have fueled a rapid expansion of the market for prefilled syringes, with worldwide sales estimated to exceed 1 billion units and annual sales expected to grow at a rate in excess of 10% (2, 3).

Figure 1
The basic components of a prefilled syringe are illustrated in Figure 1. The syringe barrel is typically either made from Type 1 borosilicate glass or various plastic materials (e.g., polypropylene, cyclic olefin polymer, cyclic olefin copolymers). Other components (e.g., tip cap and plunger) are typically made from elastomeric materials, which may be surface coated. Syringe barrels and plungers are typically coated with an agent (e.g., silicone oil) to facilitate plunger movement. Plunger movement is accomplished by an attached piston rod (typically plastic).

In the US Food and Drug Administration's Guidance for Industry, Container Closure Systems for Packaging Human Drugs and Biologics, the agency defines a container–closure system as "the sum of packaging components that together contain and protect the dosage form. This includes primary packaging components" (4). A similar definition is provided by the European Medicines Agency in its Guideline on Plastic Packaging Materials (5). It is clear from these definitions that a prefilled syringe meets the definition of a container–closure system and thus is subject to the associated guidelines and regulations. It is noteworthy that because of its use and nature, a prefilled syringe, as an injectable product, falls into FDA's highest risk category for the likelihood of a packaging component–dosage form interaction.

Foremost among these regulations and guidelines are the regulatory expectations that revolve around suitability for the intended use. As noted in FDA's container–closure guidance:

Every packaging system should be shown to be suitable for its intended use: it should adequately protect the dosage form; it should be compatible with the dosage form; and it should be composed of materials that are considered safe for use with the dosage form and the route of administration. If the packaging system has a performance feature in addition to containing the product, the assembled container closure system should be shown to function properly.

Each of these aspects of suitability for intended use will be considered in greater detail as follows.


As a packaging system, a prefilled syringe must meet all the suitability-for-intended-use expectations. Only certain aspects of a given expectation may be applicable to prefilled syringes. For example, the expectation of protection of the dosage form is interpreted to mean that the prefilled syringe should protect the dosage form from factors that may degrade the quality of the dosage form throughout its shelf life. Some commonly cited causes of such degradation for prefilled syringes include loss of solvent, adsorption of water vapor, and microbial contamination. Other potential causes of degradation, including light exposure and contact with reactive gases, are less germane to mainstream applications of prefilled syringes because such systems are not currently marketed as light or gas barriers.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here